Articles

O3 Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis

BJH - 2018, issue Abstract Book BHS, february 2018

T. Demuynck , P. Vandenberghe MD, PhD, G. Verhoef MD, PhD, T. Devos MD, PhD

Read more

P17 Concurrent driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients

BJH - 2018, issue Abstract Book BHS, february 2018

L. De Roeck , L. Michaux MD, PhD, K. Debackere , E. Lierman PhD, P. Vandenberghe MD, PhD, T. Devos MD, PhD

Read more

P37 Comparison of Multigam® IV (5% vs. 10%) in hematological patients with secondary immunodeficiencies to evaluate infusion time, tolerability and satisfaction. A monocentric observational Belgian study

BJH - 2018, issue Abstract Book BHS, february 2018

Ir J. Van Ham , M. Delforge MD, PhD, A. Janssens MD, PhD, J. Raddoux , M. Beckers MD, PhD, T. Devos MD, PhD, D. Dierickx MD, PhD, V. Vergote MD, J. Maertens MD, PhD, H. Schoemans MD, PhD, P. Vandenberghe MD, PhD

Read more

Highlights in myeloproliferative neoplasms

BJH - volume 8, issue 1, february 2017

T. Devos MD, PhD

SUMMARY

The presentations on myeloproliferative neoplasms at this year’s ASH congress were inspiring and innovative. As expected, the main topic in chronic myeloid leukemia (CML) was treatment-free remission (TFR). About 30 oral or poster abstracts on this topic were presented during ASH 2016. An update of the important EURO-SKI trial and new results were presented: TFR-studies after treatment with 1st and 2nd generation tyrosine kinase inhibitors (TKI), as well as TFR-studies after both first and second attempts of TKI-discontinuation. While stopping TKI-treatment is considered in CML, starting new treatments and when to start was the main topic regarding the BCR-ABL negative MPNs polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF). A wide panoply of MPN-related topics has been presented at San Diego: late-breaking results of the second-generation JAK-inhibitor pacritinib in MF, interferon-trials in PV and ET, long-term treatment data of the JAK-TKI momelotinib and ruxolitinib, new molecules and novel molecular data, and finally, a special focus on quality of life (QOL). QOL has been a major topic in CML/MPN since several years. In this paper, some key abstracts on CML and MPN, presented at ASH 2016, are selected and commented. I’m aware that this selection excludes many other abstracts, not reducing their intrinsic value. The aim is to present a broad and representative spectrum of studies on each topic. At the end of the article, some ‘take-home messages’ will be given.

(BELG J HEMATOL 2017;8(1):16–22)

Read more

The role of myeloid-derived suppressor cells in haematology: hype or reality?

BJH - volume 7, issue 6, december 2016

M. Beckers MD, PhD, D. Dierickx MD, PhD, T. Devos MD, PhD, S. Fevery MD, PhD, B. Sprangers MD, PhD

Summary

One of the hallmarks of failure of elimination of malignant cells by activated T-cells is the immunosuppressive environment of the tumour. Myeloid-derived suppressor cells contribute to this immunosuppressive environment by inhibition of the adaptive and innate immune system. In this article we describe the current knowledge of the role of myeloid-derived suppressor cells in the progression of haematological malignancies.

(BELG J HEMATOL 2016;7(6):213–6)

Read more

Discontinuation of imatinib in Belgian patients with chronic myeloid leukaemia

BJH - volume 7, issue 5, october 2016

P. Mineur MD, C. Doyen MD, PhD, N. Straetmans MD, PhD, K. Van Eygen MD, D. Pranger MD, A. Bosly MD, PhD, M. André MD, PhD, T. Devos MD, PhD, L. Knoops MD, PhD, On behalf of the MPN Belgian Hematological Society subcommittee

Summary

This article describes the Belgian register of chronic myeloid leukaemia patients who have stopped their treatment with imatinib in conditions comparable to the French STIM trial results: 44% remained in major molecular response off therapy; relapses appear rapidly after stopping imatinib and are responsive when the treatment is resumed.

(BELG J HEMATOL 2016;7(5):184–6)

Read more

P2.02 Belgian consensus on the diagnosis and management of Paroxysmal Nocturnal Hemoglobinuria

BJH - volume 7, issue Abstract Book BHS, january 2016

dr. B. Devalet , N. Boeckx MD, PhD, B. Chatelain PharmD, C. Chatelain MD, D. Deeren , A. Gothot MD, PhD, S. Meers MD, PhD, T. Devos MD, PhD

Read more
X